JP2022515650A5 - - Google Patents
Info
- Publication number
- JP2022515650A5 JP2022515650A5 JP2021538205A JP2021538205A JP2022515650A5 JP 2022515650 A5 JP2022515650 A5 JP 2022515650A5 JP 2021538205 A JP2021538205 A JP 2021538205A JP 2021538205 A JP2021538205 A JP 2021538205A JP 2022515650 A5 JP2022515650 A5 JP 2022515650A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- compound
- subject
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862786991P | 2018-12-31 | 2018-12-31 | |
| US62/786,991 | 2018-12-31 | ||
| PCT/US2019/069059 WO2020142486A1 (en) | 2018-12-31 | 2019-12-31 | Kinase inhibitor compounds and compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515650A JP2022515650A (ja) | 2022-02-21 |
| JP2022515650A5 true JP2022515650A5 (cg-RX-API-DMAC10.html) | 2023-01-11 |
Family
ID=71407427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538205A Pending JP2022515650A (ja) | 2018-12-31 | 2019-12-31 | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220064146A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3906028A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2022515650A (cg-RX-API-DMAC10.html) |
| CN (1) | CN113543783A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019418800A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3124353A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020142486A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| ES3038913T3 (en) | 2018-03-20 | 2025-10-15 | Icahn School Med Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| JPWO2023008470A1 (cg-RX-API-DMAC10.html) * | 2021-07-28 | 2023-02-02 | ||
| TW202513069A (zh) | 2023-07-21 | 2025-04-01 | 美商冰洲石生物科技公司 | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200301123A (en) * | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| WO2011058139A1 (en) * | 2009-11-12 | 2011-05-19 | Selvita Sp. Z O. O. | A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| US20130102627A1 (en) * | 2010-04-09 | 2013-04-25 | The Brigham And Women's Hospital, Inc. | Acridines As Inhibitors Of Haspin And DYRK Kinases |
| AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| KR102006749B1 (ko) * | 2011-08-19 | 2019-08-02 | 디악쏘니 | Dyrk1 억제제 및 이의 용도 |
| SG11201406584TA (en) * | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| SI3057959T1 (en) * | 2013-10-17 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | DNA-PK INHIBITORS |
| AU2016315881B2 (en) * | 2015-09-03 | 2019-09-19 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| CR20180323A (es) * | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| US11279703B2 (en) * | 2016-12-01 | 2022-03-22 | Aptose Biosciences Inc. | Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof |
| EA201992676A1 (ru) * | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
-
2019
- 2019-12-31 CA CA3124353A patent/CA3124353A1/en active Pending
- 2019-12-31 CN CN201980093323.0A patent/CN113543783A/zh active Pending
- 2019-12-31 WO PCT/US2019/069059 patent/WO2020142486A1/en not_active Ceased
- 2019-12-31 JP JP2021538205A patent/JP2022515650A/ja active Pending
- 2019-12-31 EP EP19907897.3A patent/EP3906028A4/en active Pending
- 2019-12-31 US US17/418,607 patent/US20220064146A1/en active Pending
- 2019-12-31 AU AU2019418800A patent/AU2019418800A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518413A5 (cg-RX-API-DMAC10.html) | ||
| JP2022515652A5 (cg-RX-API-DMAC10.html) | ||
| US10383881B2 (en) | 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same | |
| US11066419B2 (en) | 1H-pyrrole-2,5-dione compounds and methods of using same | |
| US9744169B2 (en) | Compounds for treatment of fibrosis diseases | |
| RU2638802C2 (ru) | Применение антагонистов cxcr4 | |
| RU2008142360A (ru) | Производные амидов и их применение для лечения нарушений, связанных с белком g | |
| JP2021510153A5 (cg-RX-API-DMAC10.html) | ||
| JP2021518413A (ja) | キナーゼ阻害剤化合物及び組成物ならびに使用方法 | |
| CA2942753A1 (en) | Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| DK2930167T3 (en) | INDOLINO DERIVATIVE AS A TYROSINKINASE INHIBITOR | |
| AU2023201216A1 (en) | Methods for controlled proliferation of vestibular stem cells / generating inner ear hair cells using wnt and tgf-beta inhibition | |
| US20230234935A1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| AU2018204290A1 (en) | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds | |
| KR102596837B1 (ko) | 체세포로부터 췌장 베타 세포를 직접 분화시키는 방법 및 분화 조성물 | |
| MX2008016083A (es) | Metodo para modular la excrecion de neuritas por el uso de un antagonista del receptor de galanina-3. | |
| JP2016531111A (ja) | 代謝疾患を処置するためのppar節約化合物 | |
| CN113543783A (zh) | 激酶抑制剂化合物和组合物及使用方法 | |
| US7968535B2 (en) | Use of azapaullones for preventing and treating pancreatic autoimmune disorders | |
| JP2021503486A5 (cg-RX-API-DMAC10.html) | ||
| KR20180101228A (ko) | 신경세포 분화용 배지 조성물 및 상기 배지 조성물을 이용한 체세포로부터 신경세포로의 분화 방법 | |
| US20230364153A1 (en) | Method for direct reprogramming from somatic cells into pancreatic beta cells by using microrna, and differentiation composition | |
| JP7041877B2 (ja) | チエノ[2,3-b]ピリジン誘導体およびキノリン誘導体ならびにそれらの使用 | |
| EP2871181B1 (en) | Novel Compounds for Regeneration of Terminally-Differentiated Cells and tissues | |
| JP2022548162A (ja) | ポンペ病を処置する方法 |